Samsara BioCapital, L.P. bought $8.1M of Mineralys Therapeutics (MLYS)
Executed Mar 13 2025, disclosed Mar 17 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Mar 17 2025), the stock returned -2.5% (delay-adjusted); from the execution session (Mar 13 2025), -6.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Samsara BioCapital, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in Mineralys Therapeutics, Inc. (MLYS). Across 1 priced purchase filing, the average 21-session return was -6.4% from execution and -2.5% from disclosure (delay-adjusted; derived). The largest single filing was $8.1M of MLYS (600,000 sh × $13.50, as filed), executed Mar 13 2025.
Healthcare · Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→